A patient-first guide to understanding warm autoimmune hemolytic anemia, recognizing anemia and hemolysis symptoms, navigating diagnosis, and managing life with a rare autoimmune blood disorder. Designed to support — not replace — conversations with your healthcare team.
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune blood disorder in which the immune system produces autoantibodies that attach to healthy red blood cells and mark them for destruction. This premature red blood cell destruction is called hemolysis. Red blood cells normally circulate for about 115–120 days, but in wAIHA they may be destroyed too quickly for the bone marrow to replace them, causing anemia. It is called “warm” because the autoantibodies are active at normal body temperature or higher.
Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia in adults, accounting for approximately 70–80% of adult AIHA. It is rare, affecting roughly 1–3 adults per 100,000 people in the United States. Average age at diagnosis is approximately 50, but it can occur at any age. It is slightly more common in females. wAIHA may be mild or life-threatening and may progress slowly or quickly.
Both types involve IgG autoantibodies that attach to red blood cells and lead to their destruction.
Because wAIHA is rare, delays in recognition may occur. Patients may need access to hematology expertise, urgent evaluation during severe anemia or hemolytic crisis, and careful monitoring for complications such as blood clots.
Existing autoimmune disease such as lupus, rheumatoid arthritis, Sjögren’s disease, or Hashimoto’s disease Blood cancers or lymphoproliferative disorders such as chronic lymphocytic leukemia or non-Hodgkin lymphoma Viral infections Certain medications including some antibiotics and non-steroidal anti-inflammatory drugs
Seek emergency care immediately for difficulty breathing, chest pain, swollen or discolored red or purple limb, unexplained cough, confusion, severe head pain, weakness, or visual changes. These may suggest severe anemia, blood clot, pulmonary embolism, stroke-like symptoms, or another urgent complication.
Disease activity may worsen slowly or rapidly. Flares can involve increased red blood cell destruction, worsening anemia, jaundice, dark urine, fatigue, shortness of breath, dizziness, or need for urgent treatment.
Symptoms can be nonspecific and may overlap with other causes of anemia, fatigue, jaundice, shortness of breath, dizziness, and weakness. Because wAIHA is rare, patients may need hematology consultation and repeat testing during changing disease activity.
Warm autoimmune hemolytic anemia is typically diagnosed by a hematologist. Diagnosis focuses on confirming anemia, showing that red blood cells are being destroyed too quickly, and identifying immune markers on red blood cells. Additional testing may look for underlying autoimmune disease, infection, medication triggers, or blood cancers.
Evaluation for lupus, rheumatoid arthritis, Sjögren’s disease, Hashimoto’s disease, and other autoimmune disorders Evaluation for chronic lymphocytic leukemia, non-Hodgkin lymphoma, and other lymphoproliferative disorders Infection review Medication review, including antibiotics and NSAIDs Assessment for clotting risk and complications
Treatment for warm autoimmune hemolytic anemia focuses on suppressing the immune system enough to stop red blood cell destruction, treating severe anemia, preventing complications, and reducing relapse risk. There are profound unmet needs, and treatment may include corticosteroids, biologics, immunosuppressants, transfusions, splenectomy, and supportive therapies.
Tavalisse (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor, is in later-stage clinical development for wAIHA. It is designed to block signals in the spleen that contribute to premature red blood cell destruction. Additional therapies are being studied to address unmet needs and relapse risk.
Living with wAIHA often requires monitoring symptoms, managing fatigue, tracking lab trends, preparing for relapse, and staying alert to clotting or severe anemia symptoms. Because disease activity may change quickly, communication with the healthcare team is essential.
Fatigue and weakness may be significant when hemoglobin is low. Patients may need pacing, rest periods, reduced exertion during flares, and support with work, caregiving, or daily activities while anemia is active.
Track fatigue, weakness, dizziness, shortness of breath, dark urine, jaundice, heart rate changes, and any symptoms that appear during medication tapering or after treatment changes.
wAIHA can increase risk for blood clots such as DVT or PE. Patients should report limb swelling, pain, redness, purple discoloration, chest pain, shortness of breath, unexplained cough, or sudden neurologic symptoms urgently.
Corticosteroids and immunosuppressants may increase infection risk and cause side effects. Patients should keep an updated medication list, report fevers or concerning reactions, and ask about vaccines, infection precautions, bone health, and blood sugar monitoring.
Patients may qualify for workplace accommodations under the Americans with Disabilities Act (ADA), including flexible scheduling, remote work, rest breaks, time off for infusions or lab monitoring, and temporary reduced physical demands.
Many people with wAIHA report fear, anxiety, or worry about disease burden and relapse. Mental health support is an important part of rare disease care, especially when symptoms can become urgent or life-threatening.
Mental health symptoms are not weakness. Living with a rare blood disorder, relapse risk, and urgent symptoms can be emotionally heavy — and support belongs in your care plan.
Tell your hematologist or primary care provider about anxiety, depression, or fear of relapse. Ask for referral to a therapist familiar with chronic illness or rare disease. Connect with rare disease or autoimmune blood disorder communities. Create an emergency plan to reduce uncertainty. Call or text 988 during a mental health crisis.
Rate each symptom from 1 (mild) to 5 (severe). Bring this filled out to your appointments — it helps your provider see patterns and adjust your care.
This guide is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for guidance specific to your situation.
